Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Abivax ( ABVX +0.26%), a France-based biotech, saw its shares skyrocket by more than 1,740% last year after it made ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Upslope Capital Management, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the ...

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.